These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21421726)

  • 41. A positron emission tomography occupancy study of brexpiprazole at dopamine D
    Girgis RR; Forbes A; Abi-Dargham A; Slifstein M
    Neuropsychopharmacology; 2020 Apr; 45(5):786-792. PubMed ID: 31847007
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
    Uchida H; Mamo DC; Kapur S; Labelle A; Shammi C; Mannaert EJ; Mann SW; Remington G
    J Clin Psychiatry; 2008 Aug; 69(8):1281-6. PubMed ID: 18642974
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decreased 5-HT2a receptor binding in patients with anorexia nervosa.
    Audenaert K; Van Laere K; Dumont F; Vervaet M; Goethals I; Slegers G; Mertens J; van Heeringen C; Dierckx RA
    J Nucl Med; 2003 Feb; 44(2):163-9. PubMed ID: 12571204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of cortical 5-HT2A receptor binding in bulimia nervosa patients and healthy volunteers.
    Goethals I; Vervaet M; Audenaert K; Van de Wiele C; Ham H; Vandecapelle M; Slegers G; Dierckx R; van Heeringen C
    Am J Psychiatry; 2004 Oct; 161(10):1916-8. PubMed ID: 15465993
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.
    Gründer G; Fellows C; Janouschek H; Veselinovic T; Boy C; Bröcheler A; Kirschbaum KM; Hellmann S; Spreckelmeyer KM; Hiemke C; Rösch F; Schaefer WM; Vernaleken I
    Am J Psychiatry; 2008 Aug; 165(8):988-95. PubMed ID: 18381901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.
    Kessler RM; Ansari MS; Riccardi P; Li R; Jayathilake K; Dawant B; Meltzer HY
    Neuropsychopharmacology; 2005 Dec; 30(12):2283-9. PubMed ID: 16123775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients.
    Erritzoe D; Rasmussen H; Kristiansen KT; Frokjaer VG; Haugbol S; Pinborg L; Baaré W; Svarer C; Madsen J; Lublin H; Knudsen GM; Glenthoj BY
    Neuropsychopharmacology; 2008 Sep; 33(10):2435-41. PubMed ID: 18288096
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
    Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
    Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 5-HT2A receptors in the feline brain: 123I-5-I-R91150 kinetics and the influence of ketamine measured with micro-SPECT.
    Waelbers T; Polis I; Vermeire S; Dobbeleir A; Eersels J; De Spiegeleer B; Audenaert K; Slegers G; Peremans K
    J Nucl Med; 2013 Aug; 54(8):1428-33. PubMed ID: 23819924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.
    Lian J; Huang XF; Pai N; Deng C
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():62-8. PubMed ID: 23994047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.
    Liem-Moolenaar M; Rad M; Zamuner S; Cohen AF; Lemme F; Franson KL; van Gerven JM; Pich EM
    Br J Clin Pharmacol; 2011 Jun; 71(6):907-16. PubMed ID: 21223356
    [TBL] [Abstract][Full Text] [Related]  

  • 53. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.
    Potkin SG; Keator DB; Kesler-West ML; Nguyen DD; van Erp TG; Mukherjee J; Shah N; Preda A
    CNS Spectr; 2014 Apr; 19(2):176-81. PubMed ID: 24073841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simultaneous in-vivo receptor occupancy assays for serotonin 1A, 2A, and dopamine 2 receptors with the use of non-radiolabelled tracers: Proposed method in screening antipsychotics.
    Thentu JB; Nirogi R; Bhyrapuneni G; Ajjala DR; Aleti RR; Palacharla RC
    J Pharmacol Toxicol Methods; 2017; 85():22-28. PubMed ID: 28063918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of serotonin-2A receptor occupancy with 123I-5-I-R91150 and single-photon emission tomography before and after low-dose pipamperone administration in the canine brain.
    Peremans K; De Spiegeleer B; Buntinx E; Dobbeleir A; Vermeire S; Vandermeulen E; De Vos F; Megens A; Eersels J; Audenaert K
    Nucl Med Commun; 2008 Aug; 29(8):724-9. PubMed ID: 18753826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D₂-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D₂-receptor occupancy.
    Hoeben E; Neyens M; Mannaert E; Schmidt M; Vermeulen A
    Clin Pharmacokinet; 2013 Nov; 52(11):1005-15. PubMed ID: 23754735
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
    J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.
    Catafau AM; Corripio I; Pérez V; Martin JC; Schotte A; Carrió I; Alvarez E
    Psychiatry Res; 2006 Dec; 148(2-3):175-83. PubMed ID: 17059881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development.
    Talbot PS; Laruelle M
    Eur Neuropsychopharmacol; 2002 Dec; 12(6):503-11. PubMed ID: 12468013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.